The Broad Institute, Inc.

Bayer Pharma Aktiengesellschaft

Dana-farber-cancer Institute Inc.

Bayer Aktiengesellschaft

Ucb S.a.

Massachusetts Institute of Technology

The University of Texas System

Harvard College

The General Hospital Corporation

Rutgers, the State University of New Jersey

The Brigham and Women's Hospital, Inc.

Massachusetts General Hospital Corporation

Sam Houston State University

Eye T. Plus, LLC

Timothy A Lewis

Heidi Greulich

Philip Lienau

Matthew Meyerson

Martin Lange

Xiaoyun Wu

Benito Munoz

Manuel Ellermann

Charlotte Christine Kopitz

Alex Burgin

Xiong Cai

Adrian Tersteegen

Detlev Sülzle

Stefan Nikolaus Gradl

Knut Eis

Antje Margret Wengner

Pierre P Chatelain

Sajjat Hussoin

Gurmit Grewal

Anna Toy-Palmer

Eamon Comer

Ralph Scannell

Nobutaka Kato

Jun Pu

Jeremy Duvall

Christina Scherer

Marie-Agnes Lassoie

Jennifer A Beaudoin

Bertrand Braibant

James Ellis

Christa Hegele-Hartung

Jessica Bastien

Morgane Sayes

Matthew Leighty

Edmond Differding

Sivaraman Dandapani

Partha Pratim Nag

Ulrike Sack

Luc De Waal

Monica Schenone

Michelle Young

David T Scadden

Monty Krieger

Tomohiko Kawate

Detlef Stöckigt

Deborah Hung

David B Sykes

Longqin Hu

Andreas Janzer

Miao Yu

Chris Dockendorff

Willmen Youngsaye

Patrick Faloon

Sarah Grant

Thomas Nieland

Lara Nicole Gechijian

Hanna Meyer

Marjorie A Zielke

Michael Kaiser

Christopher Gonzales

Cecelia Marquart

John F Kay

Gary Hardee

Matthew Dusek

Kenneth Authier

Sadagopan Magesh

Lin Chen

Ben Munoz

Lili Wang

Lucian De Waal

Edmund Differding

The present invention includes name compounds of general formula (I): (I) in which R, R, Rand Rare as defined herein, methods for their preparation, pharmaceutical compositions and combinations comprising said compounds, and their use for the treatment of hyperproliferative diseases.

1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases

The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R, R, R, and R, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.

Dihydrooxadiazinones

The present invention features improved compounds, especially methods of identifying patients having cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).

Compounds, compositions and methods for cancer patient stratification and cancer treatment

The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives of formula (I): The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives of formula (I):

6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer

The present invention provides dihydrooxydiazinone compounds of general formula (I) in which R, R, R, and R, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.

The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R, R, R, and R, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients. 

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.

Compounds and methods for the treatment of malaria

The present invention features improved compounds, especially the compound having the structure (1). Compositions and methods of identifying patients having cancer using biomarkers (e.g., PDE3A, PDE3B, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention. 

Compounds, compositions and methods for cancer treatment

The present invention includes methods of treating patients with acute myeloid leukemia across a range of genetic subtypes with DHODH inhibitors, such as 6-fluoro-2-(2'-fluoro-[1,1&#x2032;-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid).

Compounds and methods useful for treating or preventing hematological cancers

The present invention features improved Compounds, especially (I) methods of identifying patients having Cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein). 

A training system includes a computer system, a display system and a motion capture device. During use the training system presents a computer simulation of a virtual subject capable of exhibiting nystagmus to a trainee. The movements of the trainee are captured using the computer system during the administration of an HGN test to the virtual subject. During the administration of the HGN test to the virtual subject, the training system simulates nystagmus in the virtual subject.

Individual nystagmus simulated training experience

Disclosed are compounds that can be used for treating tuberculosis.

Compounds for the treatment of tuberculosis

A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed.

Direct inhibitors of Keap1-Nrf2 interaction as antioxidant inflammation modulators

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria. 

Growing community of inventors

Marlborough, MA, United States of America

Timothy A Lewis